MedTrace Logo

Study of EC0225 for the Treatment of Refractory or Metastatic Tumors

NCT00441870 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2012-03-09

No results posted yet for this study

Summary

This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.

Conditions

Interventions

DRUG

EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)

Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)

DRUG

99mTC-EC20 (Folic acid-technetium 99m conjugate)

20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging

Sponsors & Collaborators

  • Endocyte

    lead INDUSTRY

Principal Investigators

  • Richard A. Messmann, MD, MHS, MSc · Endocyte

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441870 on ClinicalTrials.gov